Wnt signaling potentiates neèogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 40, 2013, Pages 16009-16014

  Pawlikowski, Jeff S ^a,b   McBryan, Tony ^a,b   Èan Tuyn, John ^a,b   Drotar, Mark E ^a,b   Hewitt, Rachael N ^a,b   Maier, Andrea B ^c   King, Ayala ^a   Blyth, Karen ^b   Wu, Hong ^d   Adams, Peter D ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CXCL2 CHEMOKINE; CYCLIN A2; CYCLIN D1; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRILYSIN; MELAN A; VASCULOTROPIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL AGING; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NEVUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; WNT SIGNALING PATHWAY;

ANIMALS; CELL AGING; CELL LINE, TUMOR; DNA PRIMERS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; MICE; MICROARRAY ANALYSIS; NEVUS; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; WNT SIGNALING PATHWAY;

EID: 84885081894     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303491110     Document Type: Article

References (55)

1. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593-602.
2. Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25:585-621.
3. Michaloglou C, et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436(7051):720-724.
4. Coppé JP, Desprez PY, Krtolica A, Campisi J (2010) The senescence-associated secretory phenotype: The dark side of tumor suppression. Annu Rev Pathol 5:99-118.
5. Chen Z, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436(7051):725-730.
6. Collado M, et al. (2005) Tumour biology: Senescence in premalignant tumours. Nature 436(7051):642.
7. Braig M, et al. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436(7051):660-665.
8. Xue W, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128):656-660.
9. Robinson WA, et al. (1998) Human acquired naevi are clonal. Melanoma Res 8(6): 499-503.
10. Omholt K, et al. (2002) Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: Mutations occur early and persist throughout tumor progression. Clin Cancer Res 8(11):3468-3474.
11. Pollock PM, et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1): 19-20.
12. Gray-Schopfer VC, et al. (2006) Cellular senescence in naevi and immortalisation in melanoma: A role for p16? Br J Cancer 95(4):496-505.
13. Suram A, et al. (2012) Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J 31(13):2839-2851.
14. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O (1989) Association of early malignant melanoma with nevocytic nevi. Cancer 63(3):550-555.
15. Smolle J, Kaddu S, Kerl H (1999) Non-random spatial association of melanoma and naevi-A morphometric analysis. Melanoma Res 9(4):407-412.
16. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544-552.
17. Vredeveld LC, et al. (2012) Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26(10):1055-1069.
18. Delmas V, et al. (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21(22):2923-2935.
19. Dhomen N, et al. (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15(4):294-303.
20. Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149(6):1192-1205.
21. Dorsky RI, Moon RT, Raible DW (1998) Control of neural crest cell fate by the Wnt signalling pathway. Nature 396(6709):370-373.
22. Dunn KJ, Williams BO, Li Y, Pavan WJ (2000) Neural crest-directed gene transfer demonstrates Wnt1 role in melanocyte expansion and differentiation during mouse development. Proc Natl Acad Sci USA 97(18):10050-10055.
23. Ikeya M, Lee SM, Johnson JE, McMahon AP, Takada S (1997) Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 389(6654):966-970.
24. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 154(2):325-329.
25. Rubinfeld B, et al. (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275(5307):1790-1792.
26. Bennett DC (2008) How to make a melanoma: What do we know of the primary clonal events? Pigment Cell Melanoma Res 21(1):27-38.
27. Widlund HR, et al. (2002) Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 158(6): 1079-1087.
28. Goodall J, et al. (2004) Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol Cell Biol 24(7):2915-2922.
29. Gallagher SJ, et al. (2013) Beta-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene 32(17):2230-2238.
30. Damsky WE, et al. (2011) β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20(6):741-754.
31. Kageshita T, et al. (2001) Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 145(2):210-216.
32. Lucero OM, Dawson DW, Moon RT, Chien AJ (2010) A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12(5):314-318.
33. Ye X, et al. (2007) Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell 27(2):183-196.
34. Narita M, et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113(6):703-716.
35. Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of proliferation. Nat Rev Cancer 6(2):99-106.
36. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H (2002) Wnt signaling controls the phosphorylation status of β-catenin. J Biol Chem 277(20):17901-17905.
37. Garraway LA, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047):117-122.
38. Bertolotto C, et al.; French Familial Melanoma Study Group (2011) A SUMOylationdefective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94-98.
39. Yokoyama S, et al. (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99-103.
40. Ramirez JA, Guitart J, Rao MS, Diaz LK (2005) Cyclin D1 expression in melanocytic lesions of the skin. Ann Diagn Pathol 9(4):185-188.
41. Bergman R, Lurie M, Kerner H, Kilim S, Friedman-Birnbaum R (1997) Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas. J Cutan Pathol 24(4):219-222.
42. King R, Googe PB, Weilbaecher KN, Mihm MC, Jr., Fisher DE (2001) Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol 25(1):51-57.
43. Smolle J, Soyer HP, Juettner FM, Hoedl S, Kerl H (1988) Nuclear parameters in the superficial and deep portion of melanocytic lesions-A morphometrical investigation. Pathol Res Pract 183(3):266-270.
44. Barnhill RL, Piepkorn M, Busam KJ, eds (2004) Pathology of Melanocytic Nevi and Malignant Melanoma (Springer, Berlin), 2nd Ed.
45. Ruhoy SM, Kolker SE, Murry TC (2011) Mitotic activity within dermal melanocytes of benign melanocytic nevi: A study of 100 cases with clinical follow-up. Am J Dermatopathol 33(2):167-172.
46. Ackermann J, et al. (2005) Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 65(10): 4005-4011.
47. Shibata H, et al. (1997) Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278(5335):120-123.
48. Ohanna M, et al. (2011) Senescent cells develop a PARP-1 and nuclear factor-κBassociated secretome (PNAS). Genes Dev 25(12):1245-1261.
49. Di Micco R, et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444(7119):638-642.
50. Courtois-Cox S, et al. (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10(6):459-472.
51. Zalaudek I, et al. (2011) Frequency of dermoscopic nevus subtypes by age and body site: A cross-sectional study. Arch Dermatol 147(6):663-670.
52. Bataille V, et al. (2007) Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol Biomarkers Prev 16(7):1499-1502.
53. Waaijer ME, et al. (2012) The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell 11(4):722-725.
54. Ressler S, et al. (2006) p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 5(5):379-389.
55. Ivanov A, et al. (2013) Lysosome-mediated processing of chromatin in senescence. J Cell Biol 202(1):129-143.